Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether the CD16- monocyte/CD16+ monocyte ratio could help predict the prognosis of DLBCL and PTCL.


Clinical Trial Description

The investigators plan to prospectively involve 100 non-hodgekin lymphoma patients, including 50 diffuse large B cell lymphomas and 50 peripheral T cell lymphomas without previous treatment from Peking Union Medical College Hospital.

The following parameters were collected: age, sex, subtype, Eastern Cooperative Oncology Group (ECOG) performance status (PS), Ann Arbor stage (I-IV), presence of B symptoms, number and type of involved sites, prognostic index including International Prognostic Index (IPI) for DLBCLand PIT for PTCL based on medical record review.

All patients would have regular treatment and follow up in PUMCH. During the follow up, treatment response was evaluated by enhanced computed tomography or PET-CT.

The peripheral blood would be collected. The Cytodiff flow cytometric technique would be used to test 16 leukocyte subpopulations from peripheral blood at the time of diagnosis, interim of treatment, end of treatment, 1 year follow-up, 1.5 year of follow-up, 2 year of follow up, 3 year of follow-up and disease progression.

Progression-free survival (PFS) and overall survival (OS) would be estimated using the Kaplan-Meier method and two-tailed log-rank test.The Cox proportional hazards model would evaluate prognostic factors for OS and PFS. Specificity, sensitivity and cut-off would be established using time-dependent receiver operating characteristic (ROC) curve analysis. Area under curve (AUC) values >0.7 indicate that the parameter can be used for diagnosis, with values >0.9 indicating high clinical accuracy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03000738
Study type Observational
Source Peking Union Medical College Hospital
Contact Wei Zhang
Phone +86-010-69151235
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date December 2016
Completion date December 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT03287817 - CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma Phase 1/Phase 2
Recruiting NCT03990961 - Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) Phase 2
Recruiting NCT04189952 - Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma Phase 2
Recruiting NCT04555811 - FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL Phase 1
Not yet recruiting NCT03873025 - A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Phase 1/Phase 2
Not yet recruiting NCT04572763 - Copanlisib Plus Venetoclax in R/R DLBCL Phase 1/Phase 2
Recruiting NCT01949818 - Treatment of Diffuse Large B Cell Lymphoma Phase 4
Completed NCT01459887 - Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma Phase 3
Completed NCT03242902 - To Decrease Fatigue With Light Therapy Phase 3
Recruiting NCT04316624 - A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy Phase 1
Recruiting NCT04104776 - A Study of CPI-0209 in Patients With Advanced Tumors Phase 1/Phase 2
Withdrawn NCT04052061 - QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma Phase 1
Recruiting NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1/Phase 2
Recruiting NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1
Not yet recruiting NCT04726787 - RadiothErapy priMIng for CAR-T N/A
Recruiting NCT04622579 - Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years Phase 2
Active, not recruiting NCT02951728 - Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma Phase 1/Phase 2
Active, not recruiting NCT01679119 - Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy Phase 2
Recruiting NCT01277172 - TREatment of degeNerative and Neoplastic Diseases With Rituximab Phase 2/Phase 3